EMA press briefing on human medicines in 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 15 January 2026, 14:00 (CET) to 15 January 2026, 14:45 (CET)

Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Date of authorisation: 09/01/2017, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Kapruvia, difelikefalin, Date of authorisation: 25/04/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Date of authorisation: 18/07/2025, Revision: 2, Status: Authorised

Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) meetings

Human medicines European public assessment report (EPAR): Obodence, denosumab, Date of authorisation: 12/02/2025, Revision: 4, Status: Authorised

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - January 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 28 January 2026, 13:00 (CET) to 28 January 2026, 15:00 (CET)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 25 February 2026, 10:00 (CET) to 25 February 2026, 12:00 (CET)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - March 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 March 2026, 10:00 (CET) to 23 March 2026, 12:00 (CET)